01—Abstract
Summary
Summary of the 10-Q filed November 1, 2023. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported third-quarter 2023 total revenues of $471.9 milliona, up from $411.7 million a year earlier, driven by net product revenues of $426.5 million (CABOMETYX $422.2 million).
However, research and development expenses rose to $332.6 millionb from $198.8 million, largely due to an $80.0 million upfront payment to Insilico for the XL309 license and higher personnel and clinical trial costs. As a result, the company recorded income from operations of $(17.6) million, compared with $82.6 million a year earlier, and net income of $1.0 million, or $0.00 per diluted share, versus $73.2 million, or $0.23 per share, in the prior-year quarter. Interest income rose to $23.1 million from $9.5 million, reflecting higher interest rates.
As of September 30, 2023, Exelixis held $1.9 billionc in cash, cash equivalents and investments, compared with $2.1 billion at December 31, 2022, and management stated it expects current resources and revenues to fund operations for at least 12 months. During the first nine months of 2023 the company repurchased $344.8 million of common stock under a program authorized in March 2023 for up to $550 million, with approximately $205.2 million remaining available for repurchases before year-end 2023. Net cash provided by operating activities for the nine months was $322.8 million.
The filing also highlights ongoing litigation over generic CABOMETYX. A settlement with Teva grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA.
The MSN II case is awaiting a judgment expected in the first half of 2024 following an October 2023 bench trial, and a Cipla ANDA case has been administratively closed. Pipeline updates include positive top-line results from the phase 3 CONTACT-02 trial in mCRPC, which met one of two primary endpoints, and a phase 3 COSMIC-313 interim overall survival analysis that did not reach statistical significance, with the trial continuing to its next analysis in 2024.
02—Key points
Key Highlights
- Total revenues were $471.9 million for the third quarter of 2023, up from $411.7 million in the third quarter of 2022.
- Net income fell to $1.0 million ($0.00 per diluted share) from $73.2 million ($0.23 per share), as R&D expenses rose to $332.6 million from $198.8 million.
- The R&D increase includes an $80.0 million upfront payment to Insilico for an exclusive global license to XL309.
- Interest income more than doubled to $23.1 million from $9.5 million, reflecting higher interest rates.
- Cash, cash equivalents and investments totaled $1.9 billion at September 30, 2023, versus $2.1 billion at December 31, 2022.
- Exelixis repurchased $344.8 million of common stock year to date under a program authorized for up to $550 million, with $205.2 million remaining for 2023.
- A Teva settlement grants Teva a U.S. license to market generic CABOMETYX beginning January 1, 2031, subject to FDA approval.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Exelixis kept $0.00.
- Revenue$471.9M100.0%
- Cost of revenue−$18.8M4.0%
- Gross profit$453.1M96.0%
- Operating costs−$470.7M99.7%
- Operating income−$17.6M3.7%
- Interest, other & tax$18.6M3.9%
- Net income$1.0M0.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 1, 2023Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $471.92M$411.74M | +14.6% |
| Cost of Revenue | $18.77M$15.30M | +22.7% |
| Gross Profit | $453.15M$396.43M | +14.3% |
| R&D Expenses | $332.58M$198.84M | +67.3% |
| SG&A Expenses | $138.14M$114.98M | +20.1% |
| Operating Expenses | $489.50M$329.13M | +48.7% |
| Operating Income | -$17.58M$82.61M | −121.3% |
| Net Income | $1.04M$73.21M | −98.6% |
| Shares Outstanding (Basic) | 315.50M322.15M | −2.1% |
| Shares Outstanding (Diluted) | 319.25M325.07M | −1.8% |
05—Questions
Frequently Asked Questions
Why did net income drop so sharply in the third quarter of 2023?
Research and development expenses increased to $332.6 million from $198.8 million, including an $80.0 million upfront payment for the Insilico license and higher personnel and clinical trial costs. This pushed the company to an operating loss of $17.6 million, which interest income of $23.1 million only partly offset, leaving net income of $1.0 million.
How strong is the CABOMETYX franchise?
CABOMETYX net product revenues were $422.2 million in the third quarter of 2023, up from $361.4 million a year earlier, and $1.19 billion for the nine months. The filing attributes growth mainly to a 11% increase in units sold for the three months, tied to the FDA approval of CABOMETYX combined with OPDIVO as a first-line treatment for advanced RCC.
What is the risk from generic competition?
Teva has a settlement that licenses it to market a generic CABOMETYX in the U.S. starting January 1, 2031, if approved by the FDA. The MSN II case is pending, with a judgment expected in the first half of 2024 after an October 2023 bench trial. The filing states that generic approval and launch could significantly decrease U.S. CABOMETYX revenues.
How much liquidity does the company have and how is it being returned to shareholders?
Exelixis had $1.9 billion in cash, cash equivalents and investments at September 30, 2023, and expects this and operating cash flows to support operations for at least 12 months. It repurchased $344.8 million of stock year to date and had about $205.2 million left under its $550 million program for 2023.
What pipeline developments were reported?
The CONTACT-02 phase 3 trial of cabozantinib with atezolizumab in mCRPC met one of two primary endpoints, showing a statistically significant PFS improvement, while the OS result was immature and the trial continues. The COSMIC-313 OS interim analyses did not reach statistical significance, so that trial continues to its next OS analysis expected in 2024. The CABINET phase 3 trial was stopped early for efficacy, with detailed results presented at ESMO on October 22, 2023.
06—Continue